Ultragenyx Pharmaceutical (RARE) Shares Outstanding (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Shares Outstanding data on file, last reported at $98.3 million in Q1 2026.

• Quarterly Shares Outstanding rose 4.69% year-over-year to $98.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98.3 million (up 4.69% YoY) and the FY2025 annual result came in at $96.6 million, up 4.43% from the prior year.
• Shares Outstanding grew to $98.3 million in Q1 2026 per RARE's latest filing, from $96.6 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $98.3 million in Q1 2026 and bottomed at $69.8 million in Q1 2022.
• The 5-year median for Shares Outstanding is $83.1 million (2024), against an average of $83.4 million.
• The widest annual swing landed in 2022, when Shares Outstanding advanced 1.23%; it then gained 28.92% in 2024.
• Tracing RARE's Shares Outstanding over 5 years: stood at $70.2 million in 2022, then climbed by 17.24% to $82.3 million in 2023, then grew by 12.39% to $92.5 million in 2024, then gained by 4.43% to $96.6 million in 2025, then rose by 1.76% to $98.3 million in 2026.
• Per Business Quant, the three latest RARE Shares Outstanding figures stand at $98.3 million (Q1 2026), $96.6 million (Q4 2025), and $96.4 million (Q3 2025).

Peer Comparison